ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.
Richard Lowenthal, co-founder, president, CEO and director, opened the session by noting the company is off to a strong start in 2026. He pointed to the completion of the firm's first full year as a commercial entity and ongoing efforts to build business momentum. Executives also released details on financial results and commercial highlights for the quarter through a press release available on the company website.